<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39367583</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-5017</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Pediatric blood &amp; cancer</Title><ISOAbbreviation>Pediatr Blood Cancer</ISOAbbreviation></Journal><ArticleTitle>Burden of SARS-CoV-2 infection prior to vaccine eligibility among immunocompromised children aged 1-11 years at a pediatric tertiary referral hospital in Toronto, Canada.</ArticleTitle><Pagination><StartPage>e31365</StartPage><MedlinePgn>e31365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pbc.31365</ELocationID><Abstract><AbstractText>SARS-CoV-2 seroprevalence reflects the efficacy of pandemic infection prevention and control measures. We performed anti-spike IgG serological testing on residual sera of children 1-11 years old at a tertiary care referral center between October and November 2021. Immunocompromised patients had the highest SARS-CoV-2 seroprevalence, at 40.5%, compared to 19.3% in non-immunocompromised patients. Targeted infection prevention and public health interventions are warranted for pediatric immunocompromised patients in future pandemics.</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petel</LastName><ForeName>Dara</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0002-2067-0223</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Mohsin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campigotto</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Microbiology, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine &amp; Pathobiology, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Science</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2855-8570</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sumit</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1334-3670</Identifier><AffiliationInfo><Affiliation>Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolotin</LastName><ForeName>Shelly</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine &amp; Pathobiology, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Vaccine Preventable Diseases, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Blood Cancer</MedlineTA><NlmUniqueID>101186624</NlmUniqueID><ISSNLinking>1545-5009</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="Y">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">immunocompromised host</Keyword><Keyword MajorTopicYN="N">pediatrics</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">seroepidemiological studies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39367583</ArticleId><ArticleId IdType="doi">10.1002/pbc.31365</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Connelly JA, Chong H, Esbenshade AJ, et al. Impact of COVID‐19 on pediatric immunocompromised patients. Pediatr Clin N Am. 2021;68(5):1029‐1054.</Citation></Reference><Reference><Citation>Freeman MC, Rapsinski GJ, Zilla ML, Wheeler SE. Immunocompromised seroprevalence and course of illness of SARS‐CoV‐2 in one pediatric quaternary care center. J Pediatr Infect Dis Soc. 2021;10(4):426‐431.</Citation></Reference><Reference><Citation>Sundberg E, Hoffman T, Nilsson A, et al. COVID‐19 seroprevalence and clinical picture in pediatric oncology and hematology patients. Pediatr Blood Cancer. 2022;69(10):e29773.</Citation></Reference><Reference><Citation>Anti‐SARS‐CoV‐2S1 Curve ELISA (IgG) instructions for use. FDA; Published 2022. Accessed July 29, 2024. https://www.fda.gov/media/152747/download</Citation></Reference><Reference><Citation>COVID‐19 vaccine bookings to open for all children aged five to 11. Ontario Newsroom; Published 2021. Accessed July 29, 2024. https://news.ontario.ca/en/release/1001195/covid‐19‐vaccine‐bookings‐to‐open‐for‐all‐children‐aged‐five‐to‐11</Citation></Reference><Reference><Citation>Science M, Bolotin S, Silverman M, et al. SARS‐CoV‐2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study. CMAJ Open. 2021;9(4):e929‐e939.</Citation></Reference><Reference><Citation>Mark C, Gibson P, Lafay‐Cousin L, et al. Outcomes of coronavirus disease 2019 infection in children and adolescents with cancer in Canada: population‐based study and systematic review. J Pediatr Hematol Oncol. 2023;45(6):e689‐e694.</Citation></Reference><Reference><Citation>Ilinca AP, Dakhallah N, Souza AM, et al. Clinical characteristics and outcomes of SARS‐CoV‐2 infection in pediatric oncology patients in the province of Quebec. Pediatr Blood Cancer. 2022;69(4):e29572.</Citation></Reference><Reference><Citation>Schober T, Caya C, Barton M, et al. Risk factors for severe PCR‐positive SARS‐CoV‐2 infection in hospitalised children. BMJ Paediatr Open. 2022;6(1):e001440.</Citation></Reference><Reference><Citation>Sundberg E, Georgantzi K, Langenskiold C, et al. Low numbers of COVID‐19 in Swedish pediatric oncology patients during the first pandemic year despite an open society. Pediatr Blood Cancer. 2022;69(10):e29750.</Citation></Reference><Reference><Citation>Weclawek‐Tompol J, Zakrzewska Z, Gryniewicz‐Kwiatkowska O, et al. COVID‐19 in pediatric cancer patients is associated with treatment interruptions but not with short‐term mortality: a Polish national study. J Hematol Oncol. 2021;14(1):163.</Citation></Reference><Reference><Citation>Hashmi SK, Bodea J, Patni T, et al. COVID‐19 in pediatric patients with acute lymphoblastic leukemia or lymphoma. JAMA Netw Open. 2024;7(2):e2355727.</Citation></Reference><Reference><Citation>Ruiz J, Aldewereld Z, Elgarten C. Chemotherapy delays due to SARS‐CoV‐2 infection in children with leukemia or lymphoma. JAMA Netw Open. 2024;7(2):e2355679.</Citation></Reference><Reference><Citation>Gorochov G, Ropers J, Launay O, et al. Serum and salivary IgG and IgA response after COVID‐19 messenger RNA vaccination. JAMA Netw Open. 2024;7(4):e248051.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>